Ensuring ADCs’ Stability and Binding with Calorimetry
Antibody-drug conjugates (ADCs) are a cutting-edge class of biopharmaceuticals transforming oncology treatment with increased specificity and efficacy. Their impact is only growing, as 14 ADCs have received global market approval to date and hundreds more are in development.












